Learn about the global adalimumab, infliximab and etanercept biosimilars market through The Business Research Company, which provides information on adalimumab, infliximab and etanercept biosimilars market size, adalimumab, infliximab and etanercept biosimilars market drivers and restraints, adalimumab, infliximab and etanercept biosimilars market players, the COVID-19 impact on the adalimumab, infliximab and etanercept biosimilars market, and more.

The global adalimumab, infliximab and etanercept biosimilars market size is expected to grow from $3.10 billion in 2021 to $4.76 billion in 2022 at a compound annual growth rate (CAGR) of 53.4%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The adalimumab, infliximab and etanercept biosimilar market is expected to reach $18.61 billion in 2026 at a CAGR of 40.6%.

The patent expiry of branded biologic drugs such as Humira, Enbrel and Remicade will drive the biosimilar market.

Request A Sample For The Global Adalimumab, Infliximab And Etanercept Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2866&type=smp

The adalimumab, infliximab and etanercept biosimilars market consists of sales of adalimumab, infliximab and etanercept biosimilar drugs by the companies that manufacture these biosimilars. Adalimumab, infliximab and etanercept biosimilar molecules are bioequivalent to original reference molecules such as Humira, Remicade and Enbrel, respectively.

Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segments Include:

By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others), Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab (Erelzi, Eticovo)

By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

The brand versions of biosimilar drugs are of high costs, which are now being replaced with biosimilar versions upon their patent’s expiry. The cost of branded biologic drugs almost doubled in recent years

TBRC’s adalimumab, infliximab and etanercept biosimilars market report covers:

Major Market Players: Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, Mylan, Hetero Drugs Ltd and Glenmark pharmaceuticals.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Time Series: Five years historic (2016-21) and ten years forecast (2022-2026-2031)

The Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2022–Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides adalimumab, infliximab and etanercept biosimilars market overviews, analyses and forecasts market size, share, adalimumab, infliximab and etanercept biosimilars market players, adalimumab, infliximab and etanercept biosimilars market segments and geographies, leading competitor revenues, profiles and market shares.

TBRC’s adalimumab, infliximab and etanercept biosimilars market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Here Is A List Of Similar Reports From The Business Research Company:

Pegfilgrastim Biosimilars Market 2022

Biosimilar Lymphocyte Modulator Global Market Report 2022

Biosimilar Therapeutic Peptides Global Market Report 2022

Interested To Know More About The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: